The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 06, 2016
Filed:
Jul. 15, 2014
Applicant:
Amderma Pharmaceuticals, Llc, Bridgewater, NJ (US);
Inventors:
Pedro Cuevas Sànchez, Madrid, ES;
Guillermo Gimenez Gallego, Madrid, ES;
Inigo Saenz de Tejada Gorman, Madrid, ES;
Javier Angulo Frutos, Valdemoro, ES;
Serafin Valverde Lopez, Madrid, ES;
Antonio Romero Garrido, Madrid, ES;
Rosa Maria Lozano Puerto, Madrid, ES;
Assignee:
AmDerma Pharmaceuticals, LLC, Bridgewater, NJ (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/185 (2006.01); A61K 31/222 (2006.01); A61K 31/255 (2006.01); A61K 31/192 (2006.01); A61K 31/216 (2006.01); A61K 45/06 (2006.01); A61K 31/225 (2006.01); C07C 59/68 (2006.01); C07C 309/24 (2006.01); C07C 309/42 (2006.01); C07C 309/68 (2006.01); C07C 309/75 (2006.01); A61K 31/235 (2006.01); C07C 57/44 (2006.01); C07C 65/03 (2006.01); C07C 65/19 (2006.01); C07C 69/017 (2006.01); C07C 69/84 (2006.01); A61K 31/10 (2006.01);
U.S. Cl.
CPC ...
A61K 31/255 (2013.01); A61K 31/10 (2013.01); A61K 31/185 (2013.01); A61K 31/192 (2013.01); A61K 31/216 (2013.01); A61K 31/222 (2013.01); A61K 31/225 (2013.01); A61K 31/235 (2013.01); A61K 45/06 (2013.01); C07C 57/44 (2013.01); C07C 59/68 (2013.01); C07C 65/03 (2013.01); C07C 65/19 (2013.01); C07C 69/017 (2013.01); C07C 69/84 (2013.01); C07C 309/24 (2013.01); C07C 309/42 (2013.01); C07C 309/68 (2013.01); C07C 309/75 (2013.01);
Abstract
The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, skin cancer.